<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166944</url>
  </required_header>
  <id_info>
    <org_study_id>201307022</org_study_id>
    <nct_id>NCT02166944</nct_id>
  </id_info>
  <brief_title>Tamoxifen Treatment in Patients With Motor Neuron Disease</brief_title>
  <official_title>The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University Shuang Ho Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND)&#xD;
      patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related&#xD;
      to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS,&#xD;
      and TDP43 can be degraded either by proteasome or autophagy pathway system. Autophagy pathway&#xD;
      can be activated by mTOR inhibition, resulting in ameliorating TDP-43 accumulation and rescue&#xD;
      in motor function in animal model. Tamoxifen had shown ability of enhance both proteasome and&#xD;
      autophagy pathway, therefore the investigators assume that Tamoxifen probably can ameliorate&#xD;
      TDP-43 accumulation and inclusion body formation in ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will assess the ALSFR-s in ALS patients at start, 1, 3, 6 and 12 months and&#xD;
      correlate the score to the neurological outcome of the patients with and without tamoxifen&#xD;
      treatment at dose of 40mg daily for one year.&#xD;
&#xD;
      The study will be able to prove the investigators hypothesis: Tamoxifen, a protease and&#xD;
      autophagy enhancer, has synergic effect with riluzole in ALS patients to slowing the&#xD;
      progression of neurological dysfunction, and respiratory insufficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Amyotrophic Lateral Sclerosis Functional Ration Scales (ALSFRS) at 1, 3, 6,12 months</measure>
    <time_frame>Baseline, month 1, 3, 6, 12</time_frame>
    <description>Amyotrophic Lateral Sclerosis Functional Ration Scales (ALSFRS) measured by a neurologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pulmonary function test at 1, 3, 6,12 months</measure>
    <time_frame>baseline, month 1, 3, 6, 12</time_frame>
    <description>Expiratory reserve volume (ERV) Forced vital capacity (FVC) Forced expiratory volume (FEV) Forced expiratory flow 25% to 75% Functional residual capacity (FRC) Maximum voluntary ventilation (MVV)&#xD;
Residual volume (RV)&#xD;
Peak expiratory flow (PEF).&#xD;
Slow vital capacity (SVC)&#xD;
Total lung capacity (TLC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in blood TDP43 related biomarkers at 1, 3, 6,12 months</measure>
    <time_frame>baseline, month 1, 3, 6, 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS Functional Ration Scale</condition>
  <condition>TAR-DNA-binding Protein-43</condition>
  <condition>Tamoxifen</condition>
  <condition>mTOR</condition>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tamoxifen 40 mg daily for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen 40 mg daily for one year</intervention_name>
    <description>both arms with riluzole daily</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosed and confirmed ALS patients, with regular follow up and oral form&#xD;
             riluzole at National Taiwan University or Shuang- Ho Hospital for more than 6 months.&#xD;
&#xD;
          2. Age â‰§20 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had already ventilator dependent, not regular followed up for more than 6&#xD;
             months or against medical advice, refuse to follow up at neurology department will be&#xD;
             excluded in this study.&#xD;
&#xD;
          2. Patients with now or previous usage of Tamoxifen&#xD;
&#xD;
          3. Patients with any contraindications of Tamoxifen usage&#xD;
&#xD;
          4. Patients with other internal medicine illiness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaur-Jong Hu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shung Ho Hospital, Taipei Meidcal University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Po-Chih Chen</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>ALS functional ration scale</keyword>
  <keyword>TAR-DNA-binding protein-43</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>mTOR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

